Endometriosis Market Analysis and Sales Forecast to 2034
Key market opportunities in the endometriosis industry include leveraging robust pipeline products, tapping into emerging markets, and forming strategic partnerships. Seven major markets dominate trends, driving revenue growth. Companies should focus on innovative products and competitive analysis to maximize opportunities.
Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) — The “Endometriosis: 68-Market Analysis and Sales Forecast” report has been added to ResearchAndMarkets.com’s offering.
Across the 68 markets, sales in the endometriosis market were $1.5 billion in 2024, growing to $4.6 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 37.5% and 45.9% in 68-market sales in 2024 and 2034, respectively.
Scope
-
This publication is an expanded version of the Excel model containing the patient-based forecast sales for endometriosis, covered in the analyst’s report “Endometriosis: Seven-Market Drug Forecast and Market Analysis to 2034”, published in June 2025. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
-
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
-
Develop business strategies by understanding the trends shaping and driving the 7MM endometriosis therapeutics market.
-
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM endometriosis therapeutics market in the future.
-
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
-
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Topics Covered:
1 Executive Summary
1.1 Overview
1.2 68M summary statistics
2 Key 7MM events driving the 68M forecast extrapolation
2.1 Abbreviations
2.2 Methodology
2.3 Primary research – key opinion leaders interviewed for this report
3 Primary research
Companies Featured
-
AbAstraZeneca
-
Abbvie
-
Debiopharma
-
Myovant Science
-
Abbott
-
Neurocine Biosciences
-
Sumitomo
-
Ipsen
-
Sanofi
-
Hope Medicine
-
Bayer
-
Pfizer
-
Kissei
-
ASKA Pharmacutical
-
Gedeon Richter
link
